Acumen means keenness and depth of perception. That’s exactly who we are: an experienced, tenacious team singularly focused on developing targeted therapies for Alzheimer’s disease, building upon current momentum to drive the field forward and achieve even better outcomes.
Toxic amyloid-beta oligomers (AβOs) are soluble protein aggregates that accumulate in the brain. They are also shown to be a primary and persistent driver of Alzheimer’s-associated neurodegeneration.
Acumen is building upon decades of research on toxic soluble amyloid beta oligomers (AβOs) to advance treatment options for Alzheimer’s disease (AD). Our most advanced candidate, ACU193, is a monoclonal antibody that selectively targets toxic soluble AβOs for the treatment of early AD. It is designed to have disease-modifying benefits with an improved safety profile, while potentially providing symptomatic benefit for Alzheimer’s patients.
